Feb. 15, 2021
Here is the link.
Disappointing news that Johnson & Johnson (NYSE: JNJ) decided to walk away from a collaboration with Geron Corp. (NASDAQ: GERN) on its only drug, imetelstat, has sent Geron’s shares reeling and cast doubt on its future. In this clip from The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell dissect what happened to help investors avoid companies with similar risks.
Phase three trial - go alone - 2018
90% clinical trial failed
65 million milestone payment -